Advertisement

Inhibition of neurogenic inflammation in abortive migraine treatment

  • Egilius L. H. Spierings
Chapter
  • 65 Downloads
Part of the Progress in Inflammation Research book series (PIR)

Abstract

Neurogenic inflammation is mediated through the release of peptides, called neuropeptides, from the sensory nerve fibers involved in nociception. It comprises two processes, plasma-protein extravasation and neurogenic vasodilation, mediated predominantly by substance P and calcitonin gene-related peptide, respectively. Substance P is released from the unmyelinated C fibers and opens up post-capillary venules by acting on neurokinin-1 receptors, allowing the extravasation of plasma proteins. Calcitonin gene-related peptide, on the other hand, is released from the small myelinated Aθ fibers and dilates the arterioles by stimulating receptors of its own.

Keywords

Dura Mater Trigeminal Ganglion Cortical Spreading Depression Neurogenic Inflammation Headache Relief 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chapman LF, Ramos AO, Goodell H et al (1960) A humoral agent implicated in vas-cular headache of the migraine type. Arch Neurol 3: 223–229PubMedCrossRefGoogle Scholar
  2. 2.
    Graham JR, Wolff HG (1938) Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiat 39: 737–763CrossRefGoogle Scholar
  3. 3.
    Spierings ELH (2000) The (suma)triptan history revisited (letter). Headache 40:766–767PubMedCrossRefGoogle Scholar
  4. 4.
    Buzzie MG, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99: 202–206CrossRefGoogle Scholar
  5. 5.
    Earl NL, McDonald SA, Lowy MT (1999) Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine (abstract). Cephalalgia 19: 357Google Scholar
  6. 6.
    Manilla BG, Cutler N, Leibowitz MT et al (2001) Safety and efficacy of PNU-142633 a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia; in press Google Scholar
  7. 7.
    Johnson KW, Schaus JM, Durkin MM et al (1997) 5-HT1F receptor agonists inhibit neurogenic durai inflammation in guinea pigs. Neuroreport 8: 2237–2240PubMedCrossRefGoogle Scholar
  8. 8.
    Shepheard S, Edvinsson L, Cumberbatch M et al (1999) Possible antimigraine mecha-nisms of action of the 5HTIF receptor agonist LY334370. Cephalalgia 19: 851–858PubMedCrossRefGoogle Scholar
  9. 9.
    Goldstein DJ, Roon KI, Offen WW et al (1999) Migraine treatment with selective 5-HT1F receptor agonist (SSOFRA) LY334370 (abstract). Cephalalgia 19: 318Google Scholar
  10. 10.
    Lee WS, Moskowitz MA (1993) Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 626: 303–305PubMedCrossRefGoogle Scholar
  11. 11.
    Gupta P, Brown D, Butler P et al (1995) The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 116: 2385–2390PubMedCrossRefGoogle Scholar
  12. 12.
    Shepheard SL, Williamson DJ, Beer MS et al (1997) Differential effects of 5-HT1B/1D receptor agonists on neurogenic durai plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 36: 525–533CrossRefGoogle Scholar
  13. 13.
    Roon KI, Olesen J, Diener HC et al (2000) No acute antimigraine efficacy of CP122288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 47: 238–241PubMedCrossRefGoogle Scholar
  14. 14.
    Clozel M, Breu V, Gray GA (1994) Pharmacological characterization of bosetan, a new potent orally active non-peptide endothelin receptor antagonist. J Pharmacol Exp Ther 270: 228–235PubMedGoogle Scholar
  15. 15.
    Brändli P, Löffler BM, Breu V et al (1996) Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64: 315–322PubMedCrossRefGoogle Scholar
  16. 16.
    May A, Gijsman HJ, Wallnöfer et al (1996) Endothelin antagonist bosetan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67: 375–378PubMedCrossRefGoogle Scholar
  17. 17.
    Smith MI, Read SJ, Chan WN et al (2000) Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 20: 546–553PubMedCrossRefGoogle Scholar
  18. 18.
    Maassen van den Brink A, Van den Broek RWM, De Vries R et al (2000) The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia 20: 538–545CrossRefGoogle Scholar
  19. 19.
    Moussaoui SM, Garret C (1997) Are substance P antagonists potential treatment for migraine and related headaches, pain, and emesis? In: J Olesen, P Tfelt-Hansen (eds): Headache treatment: trial methodology and new drugs. Lippincott-Raven Publishers, Philadelphia, 303–311Google Scholar
  20. 20.
    Lee WS, Moussaoui S, Moskowitz MA (1994) Blockade of oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol 112: 920–924PubMedCrossRefGoogle Scholar
  21. 21.
    Phebus LA, Johnson KW, Stengel PW et al (1997) The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sciences 60: 1553–1561PubMedCrossRefGoogle Scholar
  22. 22.
    Goldstein DJ, Wang O, Saper JR et al (1997) Ineffectiveness of neurokinin-1 antagonists in acute migraine: a crossover study. Cephalalgia 17: 785–790PubMedCrossRefGoogle Scholar
  23. 23.
    Newby DE, Sciberras DG, Ferro CJ et al (1999) Substance P-induced vasodilation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. Br J Clin Pharmacol 48: 336–344PubMedCrossRefGoogle Scholar
  24. 24.
    Norman B, Panebianco D, Block GA (1998) A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine (abstract). Cephalalgia 18: 407Google Scholar
  25. 25.
    Polley JS, Gaskin PJ, Perren MJ et al (1997) The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system. Regulatory Peptides 68: 23–29PubMedCrossRefGoogle Scholar
  26. 26.
    Connor HE, Bertin L, Gillies S et al (1998) Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine (abstract). Cephalalgia 18: 392Google Scholar
  27. 27.
    Doods H, Hallermayer G, Wu D et al (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129: 420–423PubMedCrossRefGoogle Scholar
  28. 28.
    Goldstein DJ, Offen WW, Klein EG, Phebus LA (1999) Lanepitant, an NK-1 antagonist, in migraine prophylaxis (abstract). Cephalalgia 19: 377Google Scholar

Copyright information

© Springer Basel AG 2002

Authors and Affiliations

  • Egilius L. H. Spierings
    • 1
  1. 1.Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations